We are live on ! Find out more
SVA

Sinovac Biotech, Ltd
SVA

Delisted

SVA was delisted on the 22nd of February, 2019.

Back to rankings

37 hedge funds and large institutions have $118M invested in Sinovac Biotech, Ltd in 2017 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 10 increasing their positions, 10 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 6

23% more call options, than puts

Call options by funds: $266K | Put options by funds: $217K

9% more capital invested

Capital invested by funds: $108M → $118M (+$9.47M)

6% more funds holding

Funds holding: 35 → 37 (+2)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 10

Holders
37
Holders Change
+2
Holders Change %
+5.71%
% of All Funds
0.92%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
8
Increased
10
Reduced
10
Closed
6
Calls
$266K
Puts
$217K
Net Calls
+$49K
Net Calls Change
+$38K

Top Buyers

Rank Fund Capital Flow
1
GP
GLG Partners
United Kingdom
+$916K
2
Renaissance Technologies
Renaissance Technologies
New York
+$739K
3
WAM
Wolverine Asset Management
Illinois
+$432K
4
Walleye Trading
Walleye Trading
New York
+$264K
5
Group One Trading
Group One Trading
Illinois
+$159K

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$9.42M
2
Two Sigma Investments
Two Sigma Investments
New York
-$708K
3
PAM
Panagora Asset Management
Massachusetts
-$90.6K
4
CAM
ClariVest Asset Management
California
-$83K
5
OAC
OMERS Administration Corp
Ontario, Canada
-$80K
Name Holding Trade Value Shares
Change 		Change in
Stake
AIM
26
Acrospire Investment Management
Illinois
$34K -$22.2K -4,054 -45%
FPF
27
FNY Partners Fund
New York
$33K -$49.7K -9,064 -64%
IA
28
IFP Advisors
Florida
$14K +$5.48K +1,000 +100%
Simplex Trading
29
Simplex Trading
Illinois
$12K +$9.74K +1,778 New
Wells Fargo
30
Wells Fargo
California
$8K – – –
UBS Group
31
UBS Group
Switzerland
$7K – – –
TRCT
32
Tower Research Capital (TRC)
New York
$6K +$4.86K +887 New
Creative Planning
33
Creative Planning
Kansas
$3K -$608 -111 -18%
Carson Wealth (CWM LLC)
34
Carson Wealth (CWM LLC)
Nebraska
$3K – – –
LTFS
35
Ladenburg Thalmann Financial Services
Florida
$2K – – –
GWM
36
Geneos Wealth Management
Colorado
$1K +$822 +150 New
Walleye Trading
37
Walleye Trading
New York
$325 +$264K +48,103 New
CAM
38
ClariVest Asset Management
California
– -$83K -14,517 Closed
OAC
39
OMERS Administration Corp
Ontario, Canada
– -$80K -13,900 Closed
CG
40
Cutler Group
California
– -$16K -2,800 Closed
Bank of America
41
Bank of America
North Carolina
– -$14K -2,500 Closed
JP Morgan Chase
42
JP Morgan Chase
New York
– -$3K -564 Closed
Citigroup
43
Citigroup
New York
– -$1K -187 Closed
1
2

SVA Hedge Fund Activity: Q2 2017 in Review

37 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Sinovac Biotech, Ltd (SVA) for Q2 2017, worth a combined $118M — up 8.7% from $108M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new SVA positions and 6 closed out — a net gain of 2 holders — while 10 added to existing stakes and 10 trimmed.

The largest buyer was GLG Partners, adding an estimated $916K. The largest seller was Morgan Stanley, cutting an estimated $9.42M.

  • 37 institutional investors held Sinovac Biotech, Ltd (SVA) as of Q2 2017, up from 35 in Q1 2017.
  • Funds reported $118M of Sinovac Biotech, Ltd stock for Q2 2017, up 8.7% quarter-over-quarter.
  • 8 funds opened new Sinovac Biotech, Ltd positions in Q2 2017 and 6 closed out, a net change of +2 holders.
  • The largest Sinovac Biotech, Ltd buyer in Q2 2017 was GLG Partners, an estimated $916K added.
  • The largest Sinovac Biotech, Ltd seller in Q2 2017 was Morgan Stanley, an estimated $9.42M sold.

Based on aggregated 13F filings for Q2 2017.